Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma

Onkologie

Volumn 28, Issue 6-7, 2005, Pages 339-344

  Chen, Shin Cheh ^a   Chang, Hsien Kun ^a,b   Lin, Yung Chang ^a   Cheung, Yun Chung ^a   Tsai, Chien Sheng ^a   Leung, Wai Man ^a   Hsueh, Swei ^a   Chen, Miin Fu ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Breast cancer, locally advanced; Epirubicin; Paclitaxel; Systemic therapy, primary

Indexed keywords

CIMETIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; FLUOROURACIL; METOCLOPRAMIDE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BREAST CARCINOMA; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CARCINOMA IN SITU; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; LEUKOPENIA; NEUTROPENIA; OUTCOMES RESEARCH; PARESTHESIA; PHASE 2 CLINICAL TRIAL; REMISSION; STOMATITIS; TREATMENT OUTCOME; TUMOR VOLUME; VAGINA BLEEDING; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; EPIRUBICIN; FEASIBILITY STUDIES; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TAIWAN; TREATMENT OUTCOME;

EID: 20444501368     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085414     Document Type: Article

References (32)

1. Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, Schell F: Multimodal treatment of locoregional advanced breast cancer. Cancer 1983;51:763-768.
2. Singletary S, McNeese M, Hortobagyi: Feasibility of breast-conservation chemotherapy for locally advanced breast carcinoma. Cancer 1992;69: 2849-52.
3. Swain SM, Sorace RA, Bagley CS, Danforth Jr DN, Bader J, Wesley MN, Steinberg SM, Lippman ME: Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987;47:3889-3894.
4. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, Ramage F, Robertshaw H, Sack N, Ebbs S: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13:424-429.
5. von Minckwitz G: Taxanes in primary systemic treatment of breast cancer. Onkologie 2003;26 (Suppl 7):21-25.
6. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kan SW, McNeese M, Stom E, Hunt K, Ames F, Hortobagyi GN: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorabicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17: 3412-3417.
7. van der Hage JA, van da Velda, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;9:4224-4237.
8. Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, Sledge GW Jr.: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999;17:3033-3037.
9. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-1466.
10. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-4174.
11. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF: A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent Neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003;9:124-133.
12. Wenzel C, Locker GJ, Pluschnig U, Zielinski CC, Rudas M, Oberhuber G, Gnant MF, Taucher S, Jakesz R, Steger GG: Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. Cancer Chem Phar 2002;50:155-159.
13. Chevallier B, Roche H, Olivier JP, Chlooet P, Hurteloup P: Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223-228.
14. National Cancer Institute: Common toxicity criteria, version 2.0. Available at: http://ctep.cancer.gov/ forms/. Accessed January 3, 2003.
15. Newman LA, Buzdar AU, Singletary SE, Kuerer HM, Buchholz T, Ames FC, Ross MI, Hunt KK: A prospective trial of preoperative chemotherapy in resectable breast cancer. Ann Surg Oncol 2002;9: 228-234.
16. Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J, Penault-Llorca F: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002;86:1041-1046.
17. Heys S: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;86:1041-1046.
18. Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon A, Vielh P, Bourstyn E: Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002;20: 1304-1310.
19. Baker AF, Dorr RT: Drug interactions with the taxanes clinical implications. Cancer Treat Rev 2001; 27:221-233.
20. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L: Improved outcomes from adding sequential paclitaxel but not from the escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
21. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
22. Gogas H, Fountailas G: The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer. Ann Oncol 2003;14:667-674.
23. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN: Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 2003;98:1150-1160.
24. Kaufmann M, Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003;21:2600-2608.
25. Ganem G, Tubiana-Hulin M, Fumoleau P, Combe M, Misset JL, Vannetzel JM, Bachelot T, De Ybarlucea LR, Lotz V, Bendahmane B, Dieras V: Phase II trial combining docetaxel and doxorubicin as Neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 2003;14:1623-1628.
26. Koenig E, Warm M, Breidenbach M, Schoendorf T, Mallmann P: Neoadjuvant chemotherapy with paclitaxel and Epirubicin in patients with primary operable breast cancer. Proc Am Soc Clin Oncol 2002, abstract no. 2022.
27. Cheung YC, Chen SC, Su MY, See LC, Hsueh S, Chang HK, Lin YC, Tsai CS: Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 2003;78:51-58.
28. von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Gademann G, Tulusan AH, Eiermann W, Graf E, Kaufmann M, German Preoperative Adriamycin-Docetaxel and German Adjuvant Breast Cancer Study Groups: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 2001;19:3506-3515.
29. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, Tomiak E, Pritchard KI, Hamilton A, Piccart MJ: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK Multicenter Study. J Clin Oncol 2003;21: 843-850.
30. Estévez LG, Cuevas JM, Anton A, Florian J, Lopez-Vega JM, Velasco A, Lobo F, Herrero A, Fortes J: Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003; 9:686-692.
31. Bertone E, Danese S, Richiardi G, Sanctis CD, Biasio M, Giardina G: Weekly concomitant administration of epidoxorubicin and paclitaxel as primary chemotherapy for T2 (> 3 cm) T4d breast cancer patients. Proc Am Soc Clin Oncol 2003;22:72.
32. Amat S, Bougnoux P, Penault-Llorca F, Fetissof F, Cure H, Kwiatkowski F, Achard JL, Body G, Dauplat J, Chollet P: Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 2003;88:1339-1345.